lorlatinib
Pre-clinicalTerminated 0 views this week 0 watching💤 Quiet
Interest: 18/100
18
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neuroblastoma
Conditions
Neuroblastoma
Trial Timeline
Mar 19, 2021 → Sep 30, 2022
NCT ID
NCT04753658About lorlatinib
lorlatinib is a pre-clinical stage product being developed by Pfizer for Neuroblastoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT04753658. Target conditions include Neuroblastoma.
What happened to similar drugs?
0 of 1 similar drugs in Neuroblastoma were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
3
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03127618 | Pre-clinical | Completed |
| NCT03178071 | Pre-clinical | Completed |
| NCT06678555 | Pre-clinical | Active |
| NCT06487078 | Pre-clinical | Recruiting |
| NCT05297890 | Phase 2 | Active |
| NCT05224609 | Phase 1 | Completed |
| NCT05144997 | Approved | Active |
| NCT04753658 | Pre-clinical | Terminated |
| NCT04362072 | Approved | Completed |
| NCT04541706 | Approved | Completed |
| NCT06282991 | Pre-clinical | Completed |
| NCT03909971 | Phase 2 | Completed |
| NCT03542305 | Phase 1 | Completed |
| NCT03505554 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Neuroblastoma